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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 43Conclusion: ErbB-inhibitors represent a new therapeutic
approach in MM. A clinical trial testing the ErbB1-inhibitor cetux-
imab and correlating response with the expression of ErbB-recep-
tors/ligands is in preparation at the University Hospitals of
Cologne, Heidelberg and Montpellier.
doi:10.1016/j.ejcsup.2006.04.103
P44. MOUSE MODELS OF SPONTANEOUS MELANOMA AS A
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V. Umansky, O. Speicher, S. Kimpfler, A. Tho¨lke, D.
Schadendorf. Skin Cancer Unit (D070), German Cancer Research
Center (DKFZ), Heidelberg, Germany.
Background: Malignant melanoma, notorious for its poor
response to currently available therapeutics, is one of the fastest
increasing cancers. Therefore, development of new alternative
treatment strategies (including immunotherapeutic ones) is
extremely important. This approach requires an establishment
of the reliable animal melanoma model that resembles human
melanoma with respect to etiology, tumor genetics, histopathol-
ogy and clinical development. We use a recently developed mouse
model of spontaneous skin melanoma, in which ret transgene (tg)
is expressed in melanocytes under the control of metallothio-
nein-I promoter (MT/Ret). Activity of the receptor tyrosine kinase,
Ret, is upregulated during the disease progression.
Methods: Immunohistology, flow cytometry, ELISPOT, ELISA, tet-
ramer staining and in vivo kill.
Results: After a short latency (2–4 months), around 30% of mice
develop skin melanoma metastasizing to lymph nodes, lungs and
brain. We found that tumors expressed melanoma associated
antigens tyrosinase, tyrosinase related protein (TRP)-1, TRP-2
and gp100, which could be applied as targets for the immunother-
apy. Ret-tg mice without tumors could mount both antigen-
unspecific (stimulation with Con A or with CD3/CD28 antibodies)
and antigen-specific (ovalbumin or TRP-2 derived peptide) T-cell
reactions, which were downregulated in melanoma bearing Ret-
tg mice. In addition, Ret-tg mice have more effector memory
and regulatory T cells than healthy (wild type) mice.
Conclusion: New strategies of melanoma immunotherapy in
this spontaneous melanoma mouse model (including therapy
with memory T cells together with dendritic cells or depletion
of regulatory T cells) will be discussed.
doi:10.1016/j.ejcsup.2006.04.104
P45. PROTEIN KINASE INHIBITORS AS MODIFIERS OF
RADIOSENSITIVITY IN GLIOBLASTOMA CELLS
M. Wang, D. Milanovic, F. Lohr, F. Wenz, C. Herskind. Department
of Radiation Oncology, Mannheim Medical Center, University of
Heidelberg, Mannheim, Germany.
Background: Protein kinase (PK) inhibitors are candidates for
modifying the response of tumour cells to anticancer agents suchas radiotherapy. The purpose of the present study was to compare
inhibition of the PI3K/Akt survival pathway by specific concentra-
tions of different PK inhibitors with changes in the radiosensitiv-
ity of glioblastoma cell lines in vitro.
Methods: Glioblastoma cell lines U343MG, U87MG and U251MG
were used. PI3K inhibitors (Wortmannin; LY294002) and receptor
tyrosine kinase (RTK) inhibitors (AG1296; AG1478; erlotinib) were
added to cultures before or after irradiation. The phosphorylation
state of Akt was detected by Western blotting. The cellular radio-
sensitivity was measured by the colony formation assay fitting
survival curves with the linear-quadratic model.
Results: The inhibitory effect of Wortmannin and LY294002 on
Akt phosphorylation depended on the cell line. However, whereas
downregulation to a variable degree was observed with 50 nM
Wortmannin, radiosensitization required micromolar concentra-
tions. RTK inhibitors had little influence on Akt phosphorylation
but moderately sensitised cells to radiation. However, the sensi-
tising effect was similar whether the inhibitor was added before
or after irradiation.
Conclusions: The results did not support a correlation between
radiosensitisation and inhibition of the PI3K/Akt survival path-
way. RTK inhibitors were not required to be present during irradi-
ation in order to sensitise cells and thus cannot be considered
classical radiosensitisers. Instead they may exert their inhibitory
effect on clonogenicity. We further conclude that signal transduc-
tion differs between glioblastoma cell lines and propose that this
might have prognostic value in vivo.
doi:10.1016/j.ejcsup.2006.04.105
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Anthony D. Hoc, Thomas O. Larsend, Alwin Kra¨mera. aClinical
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Introduction: The centrosome is a small organelle which con-
sists of two centrioles and the pericentriolar matrix. It functions
as the microtubule-organizing center of eukaryotic cells and plays
a central role in chromosome segregation and cytokinesis. Many
human malignancies harbor centrosomal aberrations, which are
caused by deregulation of centrosome duplication or cytokinesis
failure. Cells with supernumerary centrosomes usually form mul-
tipolar spindles leading to aberrant mitoses with consecutive
chromosome missegregation. To regain secondary karyotype sta-
bility after clonal selection, some tumor cells coalesce their extra
centrosomes by a poorly defined mechanism into two spindles
poles in order to divide properly.
Method: Here, we describe an automated screening strategy
designed to identify small molecules – produced by hundreds of
44 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3different fungal species – that inhibit centrosomal clustering and
thus force tumor cells with supernumerary centrosomes to
undergo multipolar mitoses and consequently apoptosis.
Results: This approach led to the identification of several sub-
stances which are currently characterized in more detail. One of
these substances is the well-known antifungal drug griseofulvin,
which, in addition to its inhibition of centrosomal clustering
described here, has recently been shown to suppress microtubule
dynamic instability.
Conclusion: Taken together, this screening may help identify
new potential anti-cancer drugs.
doi:10.1016/j.ejcsup.2006.04.106
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TRANSFER OF THE HUMAN SUPEROXIDE-DISMUTASE GENE
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Background: Protection of normal tissue against radiation-
induced damage would increase the therapeutic ratio of
radiotherapy. A promising strategy for this approach is gene
therapy-mediated overexpression of copper–zinc (CuZnSOD)
and manganese superoxide-dismutase (MnSOD). Recombinant
adeno-associated virus 2 (rAAV2) are attractive vectors owing
to their ability to infect non-dividing cells and a very low risk
of insertional mutagenesis. The purpose was to test the radio-
modulating effects of SOD on human primary lung fibroblasts
(HPLF).
Methods: Low passage HPLF (MRC5) cells were transduced with
the rAAV2-SOD vectors, harvested on day 3, irradiated (1–8 Gy)
and analysed using FACS, Western blot, SOD-activity and colony
formation assays.
Results: High transduction rates were obtained with >80% of the
HPLF cells expressing the respective SOD. Compared to transduc-
tion controls, CuZnSOD did not exhibit any radioprotective
effects, whereas for MnSOD-transduced HPLF an increase of
approximately 30% in the survival of colony-forming cells was
observed (1–4 Gy).
Conclusion: An increase in clonogenic survival (1.3-fold) of HPLF
cells after transfer of MnSOD and subsequent irradiation was
shown. Earlier, we have shown lack of protection in tumour cells
(HeLa), thus supporting that MnSOD may increase the therapeutic
ratio. rAAV2 vectors are promising tools for the delivery of radio-
protective genes in normal tissue such as the lung for pulmonary
or intestine cells for prostate irradiation.
doi:10.1016/j.ejcsup.2006.04.107
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Background: The normal development and functioning of the
prostate gland, as well as its benign and neoplastic growth is
dependent of androgen. Previous studies with Gonadotrophin
Realeasing Hormone (GnRH/LHRH) vaccines, have shown the use-
fulness of immunization against this hormone in prostate and
breast cancer.
Methods: In this work we have designed a vaccine candidate
called GnRHm1-TT based on a completely synthetic immunogen.
The peptide was formulated as a white semiviscous water in oil
preparation and injected to animals.
Results: In healthy animals, this vaccine candidate showed to
be very immunogenic, resulting in high anti-GnRH antibodies
titers, testosterone reduction and significant decrease of the
prostate and testicle weight. In tumor implanted rats the
vaccine candidate had demonstrated to produce significant
tumor growth inhibition of Dunning R3327-H androgen respon-
sive prostate tumor in rats P = 0.025 and survival increase,
P = 0.001.
Conclusion: GnRHm1-TT have demonstrated to be highly immu-
nogenic and safe, causing prostate and testicle atrophy and sig-
nificantly tumor growth inhibition. These results make our
vaccine candidate useful as an effective androgen deprivation
therapy, and possible application to prostate cancer and other
hormone-dependent malignancies therapy.
doi:10.1016/j.ejcsup.2006.04.108
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AND ANTI-METASTATIC EFFECT ON PANCREATIC CARCINOMA
CELLS AND ACTS AS AN ANTIGEN FOR d2 c/d T CELLS
Angela Ma¨rtena, Marie von Lilienfeld-Toalb, Markus W. Bu¨chlera,
Jan Schmidta. aDepartment of Surgery, University of Heidelberg, 69120
Heidelberg, Germany; bDepartment of Internal Medicine I, University of
Bonn, 53105 Bonn, Germany.
Background: Beside their use as anti resorptive drug, bisphos-
phonates are well known to stimulate cd T cells and to have direct
effects on tumor growth.
Methods: We determined the direct cytotoxic effect of pamidro-
nate and zoledronic acid, the induction of apoptosis and their
anti-metastatic potential. Next, we analyzed how bisphospho-
nates act on cd T cells propagated with our recently published
protocol. The susceptibility of pancreatic carcinoma cells pre-
treated with bisphosphonates against cd T cells was tested in
cytotoxicity assays and the subgroup involved in killing was
investigated.
